GAITHERSBURG, Md., July 20, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that it has closed two convertible note financings with new and existing investors, raising gross proceeds of $1.2 million at closing.
